Bristol-Myers Squibb Company (BMY) Dividend Safety Gauge & 10-Year DRIP Compounder
Bristol-Myers Squibb Company (BMY) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (63/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+185.6% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
$10,000 Compounded Over 10 Years → $24,333
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BMY)
- ✓Live walkthrough of BMY's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BMY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BMY. Explore sector supply chains on /butterfly.
BMY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDDoes BMY pay a dividend and is it safe?
Bristol-Myers Squibb Company (BMY) offers a 4.02% cash dividend yield ($2.47 annualized) and 5.82% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.